Healthy Skepticism Library item: 8692
Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.
Publication type: Journal Article
Ransom J.
Niche indications could drive higher valuations.
Nat Biotechnol 2006 Dec; 24:(12):1457
http://www.nature.com/nbt/journal/v24/n12/full/nbt1206-1457.html
Abstract:
Foster City, California–based Gilead surprised Wall Street with a proposal to purchase Westminster, Colorado–based Myogen on 2 October 2006 in a tender offer of $2.5 billion in cash. The acquisition could demonstrate that companies with niche applications are becoming more attractive to better-established biopharmaceutical companies.
Keywords:
Publication Types:
News
MeSH Terms:
Biotechnology/economics*
Biotechnology/organization & administration
Drug Industry/economics*
Drug Industry/organization & administration
Humans
Investments/economics*
Lung Diseases/economics
Lung Diseases/therapy
Notes:
Free full text
